Mensa Guide
Updated Antimicrobial Therapy
Free · In-App Purchases
Mensa Guide is a comprehensive antimicrobial reference designed to support optimal therapeutic decision-making in infectious diseases. Content is structured for rapid access to key information, while allowing seamless exploration of additional details through inline notes.
• Tap on any word in the text to navigate to another entry, check abbreviations, view explanatory notes, open clinical calculators, or access bibliographic references.
• Search directly from almost all screens using clinically relevant criteria, or use full-text search for more specific queries.
• Filter and explore more than 800 pathogens according to microbiological and clinical characteristics.
• Use built-in calculators to estimate serum antibiotic concentrations, glomerular filtration rate, and many more additional clinical parameters and validated scores.
• Rely on continuously updated content, regularly reviewed to reflect evolving resistance patterns, emerging pathogens and antimicrobials, epidemiological trends, and new evidence or treatment guidelines published in leading medical journals.
Note: use of the Mensa Guide requires an annual subscription of $19.99 or a monthly subscription of $1.99 (price may vary by region), with a 30-day free trial period. A subscription allows the use of the Mensa Guide on macOS, iPhone and iPad platforms.
--
About auto-renewing subscriptions:
– An in-app subscription is one month for $1.99 or one year for $19.99.
– Payment will be charged to your iTunes Account at confirmation of purchase.
– Subscriptions automatically renew unless auto-renew is turned off at least 24-hours before the end of the current period.
– Your account will be charged for renewal within 24-hours prior to the end of the current period for $1.99 or $19.99.
– Subscriptions may be managed by the user and auto-renewal may be turned off by going to the user's Account Settings after purchase.
– Any unused portion of a free trial period, if offered, will be forfeited when the user purchases a subscription to that publication, where applicable.
Terms & Conditions: http://www.garmenmed.com/terms.html
--
Disclaimer:
This app is not intended for the general public but for health care professionals. Although we make every effort to ensure that the data is accurate, we are not responsible for any errors or omissions that the app may contain. The application of the information provided in a particular situation remains the sole responsibility of the health care professional.
--
We would love to hear your suggestions, recommendations or corrections. Contact us at mensaguide@garmenmed.com
more Changes in bepirovirsen, cefiderocol, ceftolozane/tazobactam, ethambutol, islatravir, levofloxacin, monoclonal antibodies, pritelivir, rifapentine, vancomycin. Burkholderia cepacia, Kerstersia, Mycobacterium tuberculosis, nontuberculous mycobacteria, Pandoraea, Shigella, Stenotrophomonas, viridans group streptococci; Candida; Alphavirus, bunyavirus, dengue, EBV, HIV, measles, OROV, Orthobunyavirus. Allergy to antibiotics. β-lactam-resistant Enterobacterales infections. Cholecystitis. IV catheter infection. Osteomyelitis. Post-exposure prophylaxis for measles. Prevention of hemodialysis catheter infection. Prevention of infections in SOT recipients. Surgical site infection prophylaxis.
26.43 3 days ago
Fixed a bug in dark mode.
26.42.1 19 Oct
Changes in linezolid, miltefosine, olorofim, tecovirimat, tedizolid, ECOFF values (benzylpenicillin, cefalexin, cefpodoxime, cotrimoxazole, minocycline). Burkholderia cepacia, Burkholderia pseudomallei, Mycobacterium tuberculosis, Ralstonia, Staphylococcus aureus; Aspergillus, Basidiobolus, Candida, Coccidioides, Conidiobolus; Orthobunyavirus; YGTV; Blastocystis, Dientamoeba fragilis, free-living amoebae, Plasmodium falciparum. Encephalitis. Infections of the eyelid, lacrimal system, conjunctiva, or cornea. Infective endocarditis. Intra-abdominal abscesses. Sepsis and septic shock. Sinusitis. Infections in SOT recipients (prevention). Prophylaxis of invasive fungal disease in onco-hematologic patients.
26.42 17 Oct
• Added Candida score to Utilities.
• Changes in dalbavancin, meropenem, monoclonal antibodies, rifabutin, tebipenem, velpatasvir. Actinotignum, Coxiella burnetii, Helicobacter, Mycobacterium avium, Mycobacterium tuberculosis, Mycobacterium ulcerans, viridans group streptococci; Candida; CCHFV, CHIKV, EBOV, HAV, HCV, HIV, influenza, measles, SFTSV, Thogotovirus; Onchocerca. Chorioamnionitis. Guillain-Barré syndrome. IV catheter infection. Odontogenic infections. Otitis media. Pharyngotonsillitis. Pneumonia. HIV infection prophylaxis.
26.41 10 Oct
Bug fixes for iOS 18.
26.40.1 6 Oct
Changes in benznidazole, cefiderocol, clindamycin, delafloxacin, ensitrelvir, gepotidacin, glecaprevir, isavuconazole, itraconazole, nifurtimox, pibrentasvir, rifabutin, teicoplanin, terbinafine, zoliflodacin. Campylobacter, Clostridioides difficile, Enterobacter, Mycobacterium tuberculosis, Mycobacteroides chelonae, Salmonella, Staphylococcus aureus, Streptomyces; Candida, Purpureocillium, Trichophyton; CMV, EBOV, HAdV, SFTSV; Trypanosoma cruzi. β-lactam-resistant Enterobacterales infections. Cystitis. Infective endocarditis. Mycetoma. Neutropenic fever. Sepsis and septic shock. VZV vaccine.
26.40 3 Oct
Changes in amphotericin B deoxycholate, caspofungin, ceftobiprole, fosfomycin, linezolid, omadacycline, pritelivir, rifabutin. Acinetobacter, Borrelia burgdorferi, Clostridioides difficile, CoNS, Enterococcus, Helicobacter, Leptospira; Aspergillus, Candida, Coccidioides, Histoplasma, Lomentospora, Pneumocystis jirovecii, Pythium; HSV-1 and HSV-2, SARS-CoV-2. Encephalitis. Fever without an apparent source in travelers returning from the tropics. Glucocorticoids in infectious diseases. Infections during CAR T-cell therapy. Infective endocarditis. Osteomyelitis. Sepsis and septic shock.
26.39 26 Sept
Changes in cloxacillin, isoniazid, islatravir, marivabir, voriconazole. Lawsonella clevelandensis, Megasphaera, Neisseria gonorrhoeae, Neisseria meningitidis, Pandoraea, Providencia, Pseudomonas aeruginosa, Staphylococcus aureus, viridans group Streptococcus; Candida; OROV, PyV, RSV; Thelazia, Toxoplasma gondii. Encephalitis. Glucocorticoids in infectious diseases. Infectious arthritis. Infective endocarditis. Sepsis and septic shock. Skin, subcutaneous tissue, and fascia infections. Infections associated with immunosuppressive therapies (prophylaxis). Tuberculosis prevention. Rabies prophylaxis and vaccination.
26.38 19 Sept
Changes in cefazolin, cefiderocol, ceftazidime, remdesivir, vancomycin. Clostridioides difficile, Elizabethkingia, Haemophilus influenzae, Pseudomonas aeruginosa, Salmonella, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus other spp, Treponema pallidum, Weeksella; MPXV, SARS-CoV-2; Plasmodium falciparum. Biomarkers of inflammation/infection. Infectious arthritis. Mastitis and breast abscess. Prevention against H. influenzae. VZV vaccine.
26.37 12 Sept
• Added a new entry on symptomatic management in infectious diseases (covering the management of fever, pain, vomiting, diarrhea, cough, and the use of mucolytics).
• Changes in artemether/lumefantrine, bepirovirsen, rifampicin. Campylobacter, Escherichia coli, Mycobacterium tuberculosis, Pseudomonas aeruginosa, Stenotrophomonas; Aspergillus, Candida, Coccidioides, Pneumocystis jirovecii, Purpureocillium, Wickerhamomyces anomalus; ALSV; Babesia. Acute meningitis. Exacerbations of COPD. Infections of the eyelid, lacrimal system, conjunctiva, or cornea. Infective endocarditis. Neutropenic fever. Sepsis and septic shock. Prevention of infections in nursing homes.
26.36 5 Sept
• Added pritelivir to Antimicrobials.
• Changes in ciprofloxacin, dalbavancin, gepotidacin, letermovir, oseltamivir. Clostridioides difficile, Mycobacterium tuberculosis, Mycoplasma genitalium, Mycoplasma pneumoniae, Staphylococcus lugdunensis; Aspergillus, Fonsecaea, Rhizopus, Scedosporium; HHV-6, HSV, influenza, VZV; Leishmania. β-lactam-resistant Enterobacterales infections. Infective endocarditis. Pneumonia. Aspergillosis (chemoprophylaxis).
26.35 29 Aug
Changes in colistin, linezolid, vancomycin. Bacillus anthracis, Escherichia spp, Listeria, Mycobacterium tuberculosis; Trichophyton; EBOV, HIV, VZV. β-lactam-resistant Enterobacterales infections. Infections during CAR T-cell therapy. Necrotizing pneumonia. Neutropenic fever. Pneumonia. Sepsis and septic shock. CMV prophylaxis. HIV infection prophylaxis. Infections in neutropenic patients (prevention). Tuberculosis prevention.
26.34 23 Aug
Changes in amoxicillin, cefiderocol, dalbavancin, gepotidacin, isavuconazole, linezolid, quinolones, sulopenem, terbinafine, vancomycin, voriconazole. Acinetobacter, Escherichia coli, Helicobacter, Klebsiella, Leptospira, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, Stenotrophomonas; Talaromyces. Anaerobic infection. β-lactam-resistant Enterobacterales infections. Hemolytic uremic syndrome. Pneumonia. Staphylococcus aureus (chemoprophylaxis in asymptomatic carriers).
26.33 15 Aug
• Added islatravir to Antimicrobials.
• Changes in oritavancin, piperacillin/tazobactam, posaconazole, tebipenem, voriconazole. Acinetobacter, Clostridioides difficile, Clostridium tetani, Neisseria gonorrhoeae, Stenotrophomonas, Trueperella; Candida, Mucor; Trypanosoma cruzi. β-lactam-resistant Enterobacterales infections. Chorioamnionitis. Cystitis. Exacerbations of COPD. Healthcare-associated meningitis and ventriculitis. Infections in patients with major burns. Infectious diarrhea. Infective endocarditis. Pyelonephritis.
26.32 8 Aug
Changes in cefazolin, eravacycline, meropenem, rezafungin, sulbactam/durlobactam. Borrelia burgdorferi, Enterococcus, Mycobacterium tuberculosis, Pseudomonas aeruginosa; Medicopsis romeroi, Pneumocystis jirovecii; BRPV, HCV, SFTSV, TBEV, VZV. Allergy to antibiotics. Biomarkers of inflammation/infection. Fever and rhabdomyolysis. Healthcare-associated meningitis and ventriculitis. Prosthetic joint infection. Sepsis and septic shock. Skin, subcutaneous tissue, and fascia infections. STD prevention. Surgical site infection prophylaxis.
26.31 2 Aug
Changes in dolutegravir, linezolid, oritavancin. Burkholderia pseudomallei, Clostridioides difficile, Clostridium spp, Haemophilus influenzae, Haemophilus spp, Peribacillus, Staphylococcus aureus, Treponema pallidum; Candida; JCPyV, measles, Orthohantavirus. Fever of unknown origin in immunocompetent patients. Infective endocarditis. Postoperative fever. Skin, subcutaneous tissue, and fascia infections. Toxic shock syndrome. Vascular graft or endograft infection. CDI prevention.
26.30 26 Jul
Changes in cefepime, olorofim, tedizolid, temocillin, tenofovir. Actinomyces, Bartonella, Campylobacter, Clostridioides difficile, Cutibacterium, NTM, Streptococcus other spp; Aspergillus, Candida; CHIKV, HCV, hMPV, influenza; Plasmodium falciparum. Appendicitis. Fever of unknown origin in immunocompetent patients. Odontogenic infections and periodontal disease. Viral hemorrhagic fevers. Surgical site infection prevention.
26.29 18 Jul
Changes in azithromycin, aztreonam, cefazolin, cefepime/enmetazobactam, ceftazidime, ceftibuten, cloxacillin, daptomycin, letermovir, linezolid, minocycline. Acinetobacter, Elizabethkingia, Mycoplasma pneumoniae, Pseudomonas aeruginosa, Serratia, Streptococcus pneumoniae, Streptococcus pyogenes; Aspergillus; YEZV; free-living amoebae. β-lactam-resistant Enterobacterales infections. Biomarkers of inflammation/infection. Infective endocarditis. Osteomyelitis. Pneumonia. Prosthetic joint infection. Sepsis and septic shock. Chronic bronchitis, COPD (prevention of exacerbations).
26.28 11 Jul
Changes in azithromycin, molnupiravir, piperacillin/tazobactam, zoliflodacin. Burkholderia pseudomallei, Mycobacterium avium, Neisseria gonorrhoeae, NTM, Pseudomonas aeruginosa, Rickettsia prowazekii, Tropheryma whipplei; Candida, Lacazia loboi; enterovirus, HBV, influenza, Orthonairovirus, RSV, SARS-CoV-2, VZV. Bacterial prostatitis. Cystitis. Neutropenic fever. Osteomyelitis. Prosthetic joint infection. Sepsis and septic shock. Infections in SOT recipients (prevention).
26.27 4 Jul
Changes in benzylpenicillin, cefazolin, eravacycline, gepotidacin, imipenem/relebactam, liposomal amphotericin B, posaconazole, remdesivir, ribavirin, tafenoquine, temocillin. Acinetobacter, Clostridioides difficile, Enterobacter, Fusobacterium, Klebsiella, Mycobacterium tuberculosis, Staphylococcus aureus, Stenotrophomonas; Pneumocystis jirovecii, Trichophyton; HPIV, MARV; Blastocystis. Abscesses (intra-abdominal, anorectal, and prostatic). β-lactam-resistant Enterobacterales infections. Pneumonia. Pyelonephritis. Infections associated with immunosuppressive therapies (prophylaxis). Prophylaxis of invasive fungal disease in onco-hematologic patients.
26.26 27 Jun
Minor bug fixes, including a correction to the MAGIC criteria evaluation.
26.25.1 20 Jun
• Added MAGIC criteria for VGEI to Utilities.
• Changes in amoxicillin, bedaquiline, colistin, dalbavancin, fluconazole, levofloxacin, olorofim, voriconazole, zanamivir. Acinetobacter, Burkholderia pseudomallei, Clostridium spp, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Stenotrophomonas, Streptococcus gallolyticus, Treponema pallidum; Lomentospora, Mucor, Scedosporium; HHV-6, influenza, OROV. β-lactam-resistant Enterobacterales infections. Biomarkers of inflammation/infection. Sepsis and septic shock. Infections in neutropenic patients (prevention). Influenza vaccination. Surgical site infection prevention. Venous catheter infection prevention.
26.25 19 Jun
• Added bepirovirsen and cefepime/zidebactam to Antimicrobials.
• Changes in fosmanogepix, ibrexafungerp, maribavir, olorofim, and ECOFF values (aztreonam/avibactam). Sphingomonas, Stenotrophomonas; Aspergillus, Candida; CMV, Ebola, EBV, HBV, MPXV; Plasmodium falciparum. Infections in patients with liver cirrhosis. Pneumonia. Prosthetic joint infection. Asymptomatic bacteriuria (UTI prevention). RSV vaccination. Venous catheter infection (prevention).
26.24 13 Jun
• Added a PaO₂ estimation calculator (from SpO₂).
• Changes in cefiderocol, ceftriaxone, dalbavancin, eravacycline, isoniazid, tigecycline. Enterococcus, Mycobacterium tuberculosis, Pneumocystis jirovecii; CMV, SARS-CoV-2; Babesia. Prosthetic joint infection. Viral hemorrhagic fevers. CMV prophylaxis. HPV vaccination. RSV vaccination. Shingles (herpes zoster) vaccination. Surgical site infection prophylaxis. Toxoplasma gondii (prevention in hematologic patients).
26.23 6 Jun
• Added a new entry on infections in patients with major burns (under Syndromes).
• Changes in bictegravir, cabotegravir, cefiderocol, ensitrelvir, ertapenem, nitrofurantoin, pristinamycin, zoliflodacin. Chlamydia psittaci, Mycobacterium xenopi, Mycoplasma genitalium, Neisseria gonorrhoeae, Pseudomonas aeruginosa; Diutina, Purpureocillium; CMV, JCPyV, KFDV, RSV, SARS-CoV-2; Echinococcus granulosus, Leishmania. Biomarkers of inflammation/infection. Infections during CAR T-cell therapy. Pneumonia. CMV prophylaxis. RSV prevention. RSV vaccination. Tuberculosis prevention.
26.22 30 May
Changes in bepirovirsen, cefiderocol, ceftolozane/tazobactam, ethambutol, islatravir, levofloxacin, monoclonal antibodies, pritelivir, rifapentine, vancomycin. Burkholderia cepacia, Kerstersia, Mycobacterium tuberculosis, nontuberculous mycobacteria, Pandoraea, Shigella, Stenotrophomonas, viridans group streptococci; Candida; Alphavirus, bunyavirus, dengue, EBV, HIV, measles, OROV, Orthobunyavirus. Allergy to antibiotics. β-lactam-resistant Enterobacterales infections. Cholecystitis. IV catheter infection. Osteomyelitis. Post-exposure prophylaxis for measles. Prevention of hemodialysis catheter infection. Prevention of infections in SOT recipients. Surgical site infection prophylaxis.
more Version 26.43 3 days ago
Data Not Collected The developer does not collect any data from this app.
